ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

Emphasis On Early Disease In Clinical Trials, Early Lung Cancer Detection Seen As “Landmark”

September 19, 1975

NCI Program: reports Urges Expansion of Surveillance Program To Better Explain Trends

April 30, 1999

Bahama Government Closes Clinic “Immediately And Permanently” After AIDs Contamination Report

July 26, 1985

NCI Stops Trial Of Screening In Men To Add Women

November 2, 1990

NCI “Community Cancer Centers” Program in Development, House Report Reveals.

June 30, 2006

In Brief: NCI Funded To Dec. 15, No Senate Figure Yet; Speedup Urged On Interferon Manufacturing, Testing

October 10, 1980